RECHALLENGE WITH PEGYLATED LIPOSOMAL DOXORUBICIN ADDED TO TRABECTEDIN IN RECURRENT OVARIAN CANCER: A MULTICENTER, PROSPECTIVE TRIAL.(REPRAB study- MITO 36)

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-518847-40-00

Acronym

REPRAB - MITO 36

Enrollment

Registered

2024-11-25

Start date

2021-07-16

Completion date

Unknown

Last updated

2025-09-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

recurrent ovarian cancer

Brief summary

Response and progression will be evaluated according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1

Interventions

DRUGCaelyx pegylated liposomal 2 mg/ml concentrate for solution for infusion

DRUGTRABECTEDIN

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Response and progression will be evaluated according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1	—

Countries

Italy

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026